CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, ...

Dalzanemdor has failed as a treatment for cognitive impairment in Alzheimer's, Parkinson's and now Huntington's diseases Sage Therapeutics Inc.'s stock (SAGE) fell 2.4% Wednesday, headed for a fresh ...

The European Medicines Agency (EMA) granted orphan drug designation to Sage Therapeutics' (NASDAQ:SAGE) medicine SAGE-718 to treat Huntington's disease (HD). The company said SAGE-718 is being ...

Sage Therapeutics (NASDAQ:SAGE) lost more than 14% Wednesday to reach the lowest level since November amid investor concerns over its depression therapy, zuranolone, as the FDA is set to decide on its ...

My name is Emily Turvey. I specialize in working with gender issues, trauma/PTSD, teens, and highly sensitive people. I am trained in the use of EMDR and often work from client centered, narrative ...

Sage Therapeutics Inc.’s stock fell 2% early Wednesday after the company said it would cease the development of a treatment for cognitive impairment associated with Huntington’s disease after a failed ...

(Reuters) - The U.S. Food and Drug Administration on Tuesday approved Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the ...

My name is Emily Turvey. I specialize in working with gender issues, trauma/PTSD, teens, and highly sensitive people. I utilize a blend of EMDR, neural network mapping, and parts work. The parts work ...